<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930432</url>
  </required_header>
  <id_info>
    <org_study_id>BTP-21711</org_study_id>
    <nct_id>NCT04930432</nct_id>
  </id_info>
  <brief_title>Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors</brief_title>
  <official_title>A Phase I/II Study of MCLA-129, a Human Anti-EGFR and Anti-c-Met Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors, Evaluating Safety, Pharmacokinetic Characteristics and Antitumor Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in&#xD;
      patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics&#xD;
      and antitumor activity of MCLA-129.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT) in Part 1</measure>
    <time_frame>First 28 days of treatment</time_frame>
    <description>To determine the dose-limiting toxicity (DLT) of single agent MCLA-129 in patients with advanced solid tumors in Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) in Part 1</measure>
    <time_frame>First 28 days of treatment</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of single agent MCLA-129 in patients with advanced solid tumors in Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) in Part 2</measure>
    <time_frame>From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 at RP2D in patients with advanced NSCLC and other solid tumors in each corhort in Part 2 in terms of overall response rate (ORR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Event (TEAE) in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the safety of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of treatment-emergent adverse event (TEAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Half-life [t1/2] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution [VSS] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of apparent volume of distribution [VSS]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration [Tmax] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of time to reach maximum concentration [Tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time zero to time t [AUC0-t] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of area under the concentration versus time curve from time zero to time t [AUC0-t]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve [AUC0-∞] in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To evaluate the population PK profile of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of area under the concentration versus time curve [AUC0-∞]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) in Part 1</measure>
    <time_frame>From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 in terms of overall response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in Part 1 and 2</measure>
    <time_frame>From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Part 1 and 2</measure>
    <time_frame>From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Part 1 and 2</measure>
    <time_frame>From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Part 1 and 2</measure>
    <time_frame>From date of first treatment every 6 weeks until death or withdrawal, whichever came first, approximately 2 years</time_frame>
    <description>To evaluate the efficacy of MCLA-129 in patients with advanced NSCLC and other solid tumors in Part 1 and 2 in terms of overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) in Part 1 and 2</measure>
    <time_frame>Until 30 days after the last dosing</time_frame>
    <description>To assess the Incidence of anti-drug antibodies in serum blood against MCLA-129 following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine TNF-α in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in TNF-α in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IFN-γ in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IFN-γ in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IL-1β in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IL-1β in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IL-2 in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IL-2 in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IL-6 in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IL-6 in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IL-8 in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IL-8、IL-10 in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine IL-10 in Part 1</measure>
    <time_frame>Before and after each administration on day 1 and day 15</time_frame>
    <description>To assess the changes in IL-10 in serum blood following administration of MCLA-129</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MCLA-129</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose escalation phase 1 part, MCLA-129 will be administered every two weeks with increasing doses to patients with advanced solid tumors. In Part 2, patients with NSCLC and other advanced solid tumors in each corhort will be dosed with MCLA-129 every two weeks at the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCLA-129</intervention_name>
    <description>MCLA-129 will be administered by intravenous infusion.</description>
    <arm_group_label>MCLA-129</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18, regardless of gender.&#xD;
&#xD;
          -  Subjects with histologically or cytologically confirmed diagnosis of metastatic or&#xD;
             unresectable advanced NSCLC or other solid tumors (including but not limited to head&#xD;
             and neck cancer, colorectal, etc.) who have disease progression on, or were not&#xD;
             resistant to, or reject the standard treatment.&#xD;
&#xD;
          -  For Part 1, subjects must be diagnosed with EGFR positive and/or MET positive after&#xD;
             testing.&#xD;
&#xD;
          -  For Part 2, patients need to undergo the centralized biomarker testing.&#xD;
&#xD;
          -  Subjects of the dose escalation phase in Part 1 must have evaluable diseases, and&#xD;
             others must have measurable diseases as defined in RECIST v1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status scores are 0-1.&#xD;
&#xD;
          -  Expected survival is ≥3 months.&#xD;
&#xD;
          -  With certain organ system functions (without transfusion, use of blood components, or&#xD;
             G-CSF support within 14 days before testing), as defined below:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1.5×10^9 /L&#xD;
&#xD;
               -  Platelet count (PLT）≥75×10^9 /L&#xD;
&#xD;
               -  Hemoglobin (HB) ≥10 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤3×ULN&#xD;
&#xD;
               -  Creatinine ≤1.5×ULN. If creatinine is &gt;1.5×ULN, creatinine clearance is ≥50&#xD;
                  mL/min as calculated by Cockcroft-Gault formula, or ≥50 mL/min within 24 h as&#xD;
                  measured, the patients can still be included.&#xD;
&#xD;
          -  Willing to and capable of following the trial and follow-up schedule.&#xD;
&#xD;
          -  Capable of understanding the trial nature and voluntarily signing the written informed&#xD;
             consent form.&#xD;
&#xD;
          -  The subjects of Part 2 must agree that the tumor tissue samples before treatment of&#xD;
             the investigational drug can be collected or provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of certain investigational drug or antineoplastic agent within 14 days before&#xD;
             first administration of MCLA-129 or within 5 half lives (whichever is longer).&#xD;
&#xD;
          -  Execution of large surgery and radiotherapy (except focal palliative radiotherapy at&#xD;
             least 2 weeks before first administration), immunotherapy, chemotherapy (for&#xD;
             Nitrosoureas or Mitomycin C and other chemotherapeutics with delayed toxicity, it&#xD;
             shall be 6 weeks before first administration) within 4 weeks before first&#xD;
             administration of MCLA-129.&#xD;
&#xD;
          -  Patients with colorectal who are diagnosed with AS or BRAF gene mutation through&#xD;
             testing.&#xD;
&#xD;
          -  Subjects with NSCLC who previously received more than 2 lines of cytotoxicity&#xD;
             chemotherapy for treatment of focal advanced or metastatic disease (excluding&#xD;
             maintenance therapy).&#xD;
&#xD;
          -  Subjects who previously received EGFR-TKI (e.g. Poziotinib or TAK-788) that is known&#xD;
             to be effective to exon 20 insertion mutation&#xD;
&#xD;
          -  Prior use of EGFR/c-Met bispecific antibody drugs.&#xD;
&#xD;
          -  Response of toxic reactions related to prior therapy (except alopecia) not up to Grade&#xD;
             1 or below (CTCAE 5.0 criteria) before first administration of MCLA-129.&#xD;
&#xD;
          -  With other malignant tumors in the past 3 years, except cancers that have been cured&#xD;
             significantly or can be focally cured, e.g. basosquamous carcinoma of skin, carcinoma&#xD;
             cervix in situ, or in situ breast carcinoma.&#xD;
&#xD;
          -  Patients with primary malignant tumor of central nervous system, or metastases to&#xD;
             meninges, or concomitantly with symptomatic brain metastases, or new therapy naive&#xD;
             brain metastases.&#xD;
&#xD;
          -  With clinically significant cardiovascular disorder, including but not limited to:&#xD;
&#xD;
               -  Deep vein thrombosis or lung embolism diagnosed within 1 month before first&#xD;
                  administration of the investigational drug. Non-obstructive catheter related clot&#xD;
                  and other clinically irrelevant thrombosis are not included in the exclusion&#xD;
                  criteria.&#xD;
&#xD;
               -  With any of the following medical history within 6 months before first&#xD;
                  administration of the investigational drug: myocardial infarction, unstable&#xD;
                  angina, stroke, transient ischemic attack, coronary or peripheral artery bypass,&#xD;
                  or any acute coronary syndrome.&#xD;
&#xD;
               -  With abnormal ECG corrected QT interval (QTcF) at rest in the screening period.&#xD;
                  Re-measurement is made twice at an interval of 4 h above. For average QTcF of 3&#xD;
                  ECG inspections: male: ≥ 450 msec, and female: ≥ 470 msec. With clinically&#xD;
                  significant abnormal heart rate, conduction, and ECG form at rest, e.g. complete&#xD;
                  left bundle branch block, third-degree conduction block, second-degree conduction&#xD;
                  block, and PR interval &gt; 250 msec.&#xD;
&#xD;
               -  Poorly controlled hypertension in the investigator's opinion (systolic blood&#xD;
                  pressure &gt; 180 mmHg, or diastolic blood pressure &gt; 100 mmHg).&#xD;
&#xD;
               -  New York Heart Association Grade III-IV congestive heart failure, or&#xD;
                  hospitalization due to congestive heart failure within 6 months before first&#xD;
                  administration of the investigational drug.&#xD;
&#xD;
               -  Pericarditis/clinically significant pericardial effusion.&#xD;
&#xD;
               -  Cardiomyopathy.&#xD;
&#xD;
               -  With clinically significant cardiovascular disorder as believed by other&#xD;
                  investigators.&#xD;
&#xD;
          -  Active hepatitis B (hepatitis B surface antigen (HBsAg) or hepatitis B core antibody&#xD;
             (HBcAb) positive, and serum HBV DNA ≥ 2000 IU/mL (equal to 104 copies/mL)), hepatitis&#xD;
             C virus antibody, HIV antibody and treponema pallidum antibody positive.&#xD;
&#xD;
          -  Patients with Interstitial lung disease, including drug-induced Interstitial lung&#xD;
             disease or radiation pneumonitis.&#xD;
&#xD;
          -  Current severe disease or medical condition, including but not limited to uncontrolled&#xD;
             active infection, and clinically significant lung, metabolic or psychiatric disorders.&#xD;
&#xD;
          -  Women with child bearing potential, pregnant women or lactating women with pregnancy&#xD;
             test positive 7 days before treatment, and male and female unwilling to take effective&#xD;
             contraception measures or having a birth plan during the treatment and within 3 months&#xD;
             after end of treatment.&#xD;
&#xD;
          -  Patients who are known to have allergic reactions and hypersensitivity reactions, or&#xD;
             be allergic to MCLA-129 or any other excipients.&#xD;
&#xD;
          -  Patients poorly compliant, unable or unwilling to follow the study and/or follow-up&#xD;
             procedure listed in the protocol, or patients unsuitable to participate in this trial&#xD;
             in the investigator's opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanlin Chen, Master</last_name>
    <phone>18258270120</phone>
    <email>wanlin.chen@bettapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Wang, PhD</last_name>
      <phone>13910704669</phone>
      <email>zlhuxi@163.com</email>
    </contact>
    <investigator>
      <last_name>Jie Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

